Indian stock markets present attractive opportunities now. Investors with an 18-month outlook should consider deploying funds, especially i...

The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...

Around two decades ago, as Indian pharma firms first began to move into the US market, they faced many challenges, the biggest of which was...

Some time back an MNC pharma firm announced the divestment of one of its businesses in India. Another sold one of its plants. Now, with the...

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old theory that h...

In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...

While they still trade at premium valuations, they have not created wealth for shareholders. The fact is an age-old theory that just having...

In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of thes...

After the IT bull of 2000, as a new set of Indian companies took the centerstage, a number of MNCs stocks lost their shine at least on the ...

At a time when the local market is assuming the centre stage of the growth strategy for Indian pharma companies, multinational drugmakers a...

Abbott India is expected to end 2020-21 with revenue and net profit growth of 11% and 18% respectively. Besides, its debt-free status along...

Looking at the numbers, which the management was talking about, the stock still does not look very expensive, says Irani.

Every Tuesday, we will bring you a glimpse into the hottest jobs of the season.

Equity mutual funds investing in multi national companies have underperformed the broad markets, in the last one month.

Investors were seen flocking to the counters of select MNC pharma companies which have emerged as defensive bets amid choppy market conditi...

Sharmila Joshi, Co-Head PCG Sales, Emkay Global Financial Services in an interview with ET Now talks about pharmaceutical stocks.

Domestic pharmaceutical shares have outperformed their multinational (MNC) counterparts in the last month, even as the MNCs have done some ...